Status and phase
Conditions
Treatments
About
This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.
Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Marina Kupchik, MD; Tali Nachshoni, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal